158 related articles for article (PubMed ID: 24225049)
1. Inhibition of keratinocyte proliferation by phospholipid-conjugates of a TLR7 ligand in a Myc-induced hyperplastic actinic keratosis model in the absence of systemic side effects.
Crain B; Yao S; Keophilaone V; Promessi V; Kang M; Barberis A; Maj R; Mura E; Passini N; Holldack J; Ochoa R; Cottam HB; Carson DA; Hayashi T
Eur J Dermatol; 2013; 23(5):618-28. PubMed ID: 24225049
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of pathogenesis of imiquimod-induced skin inflammation in the mouse: a role for interferon-alpha in dendritic cell activation by imiquimod.
Ueyama A; Yamamoto M; Tsujii K; Furue Y; Imura C; Shichijo M; Yasui K
J Dermatol; 2014 Feb; 41(2):135-43. PubMed ID: 24387343
[TBL] [Abstract][Full Text] [Related]
3. Azithromycin impairs TLR7 signaling in dendritic cells and improves the severity of imiquimod-induced psoriasis-like skin inflammation in mice.
Huang SW; Chen YJ; Wang ST; Ho LW; Kao JK; Narita M; Takahashi M; Wu CY; Cheng HY; Shieh JJ
J Dermatol Sci; 2016 Oct; 84(1):59-70. PubMed ID: 27449383
[TBL] [Abstract][Full Text] [Related]
4. Aldara activates TLR7-independent immune defence.
Walter A; Schäfer M; Cecconi V; Matter C; Urosevic-Maiwald M; Belloni B; Schönewolf N; Dummer R; Bloch W; Werner S; Beer HD; Knuth A; van den Broek M
Nat Commun; 2013; 4():1560. PubMed ID: 23463003
[TBL] [Abstract][Full Text] [Related]
5. Imiquimod-induced TLR7 signaling enhances repair of DNA damage induced by ultraviolet light in bone marrow-derived cells.
Fishelevich R; Zhao Y; Tuchinda P; Liu H; Nakazono A; Tammaro A; Meng TC; Lee J; Gaspari AA
J Immunol; 2011 Aug; 187(4):1664-73. PubMed ID: 21765012
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of intravesical and intravenous TMX-101 and TMX-202 in a F344 rat model.
Falke J; Hulsbergen-van de Kaa CA; Maj R; Oosterwijk E; Witjes JA
Urol Oncol; 2018 May; 36(5):242.e1-242.e7. PubMed ID: 29500135
[TBL] [Abstract][Full Text] [Related]
7. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells.
Drobits B; Holcmann M; Amberg N; Swiecki M; Grundtner R; Hammer M; Colonna M; Sibilia M
J Clin Invest; 2012 Feb; 122(2):575-85. PubMed ID: 22251703
[TBL] [Abstract][Full Text] [Related]
8. Transcutaneous immunization with a novel imiquimod nanoemulsion induces superior T cell responses and virus protection.
Lopez PA; Denny M; Hartmann AK; Alflen A; Probst HC; von Stebut E; Tenzer S; Schild H; Stassen M; Langguth P; Radsak MP
J Dermatol Sci; 2017 Sep; 87(3):252-259. PubMed ID: 28655469
[TBL] [Abstract][Full Text] [Related]
9. Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2.
Hayashi T; Chan M; Norton JT; Wu CC; Yao S; Cottam HB; Tawatao RI; Corr M; Carson DA; Daniels GA
Melanoma Res; 2011 Feb; 21(1):66-75. PubMed ID: 21030882
[TBL] [Abstract][Full Text] [Related]
10. [New perspective in immunotherapy: local imiquimod treatment].
Kemény L; Nagy N
Orv Hetil; 2010 May; 151(19):774-83. PubMed ID: 20427260
[TBL] [Abstract][Full Text] [Related]
11. Toll-like receptor 7 stimulation by imiquimod induces macrophage autophagy and inflammation in atherosclerotic plaques.
De Meyer I; Martinet W; Schrijvers DM; Timmermans JP; Bult H; De Meyer GR
Basic Res Cardiol; 2012 May; 107(3):269. PubMed ID: 22543675
[TBL] [Abstract][Full Text] [Related]
12. IMQ-induced skin inflammation in mice is dependent on IL-1R1 and MyD88 signaling but independent of the NLRP3 inflammasome.
Rabeony H; Pohin M; Vasseur P; Petit-Paris I; Jégou JF; Favot L; Frouin E; Boutet MA; Blanchard F; Togbe D; Ryffel B; Bernard FX; Lecron JC; Morel F
Eur J Immunol; 2015 Oct; 45(10):2847-57. PubMed ID: 26147228
[TBL] [Abstract][Full Text] [Related]
13. Paeonol ameliorates imiquimod-induced psoriasis-like skin lesions in BALB/c mice by inhibiting the maturation and activation of dendritic cells.
Meng Y; Wang M; Xie X; Di T; Zhao J; Lin Y; Xu X; Li N; Zhai Y; Wang Y; Li P
Int J Mol Med; 2017 May; 39(5):1101-1110. PubMed ID: 28339016
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of induced nitric oxide synthase enhances the anti-tumor effects on cancer immunotherapy using TLR7 agonist in mice.
Ito H; Ando T; Ogiso H; Arioka Y; Seishima M
Cancer Immunol Immunother; 2015 Apr; 64(4):429-36. PubMed ID: 25567751
[TBL] [Abstract][Full Text] [Related]
15. Targeting aerobic glycolysis and HIF-1alpha expression enhance imiquimod-induced apoptosis in cancer cells.
Huang SW; Kao JK; Wu CY; Wang ST; Lee HC; Liang SM; Chen YJ; Shieh JJ
Oncotarget; 2014 Mar; 5(5):1363-81. PubMed ID: 24658058
[TBL] [Abstract][Full Text] [Related]
16. Recruitment of plasmacytoid dendritic cells to skin regulates treatment responsiveness of actinic keratosis to imiquimod.
Ogawa Y; Kawamura T; Matsuzawa T; Aoki R; Shimada S
J Dermatol Sci; 2014 Oct; 76(1):67-9. PubMed ID: 25088809
[No Abstract] [Full Text] [Related]
17. Gene expression in actinic keratoses: pharmacological modulation by imiquimod.
Lysa B; Tartler U; Wolf R; Arenberger P; Benninghoff B; Ruzicka T; Hengge UR; Walz M
Br J Dermatol; 2004 Dec; 151(6):1150-9. PubMed ID: 15606509
[TBL] [Abstract][Full Text] [Related]
18. Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream.
Torres A; Storey L; Anders M; Miller RL; Bulbulian BJ; Jin J; Raghavan S; Lee J; Slade HB; Birmachu W
J Transl Med; 2007 Jan; 5():7. PubMed ID: 17257431
[TBL] [Abstract][Full Text] [Related]
19. Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors.
Xiong Z; Ohlfest JR
J Immunother; 2011 Apr; 34(3):264-9. PubMed ID: 21389872
[TBL] [Abstract][Full Text] [Related]
20. Signaling through TLR7 enhances the immunosuppressive activity of murine CD4+CD25+ T regulatory cells.
Forward NA; Furlong SJ; Yang Y; Lin TJ; Hoskin DW
J Leukoc Biol; 2010 Jan; 87(1):117-25. PubMed ID: 19843574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
